0.00
100.00%
-2.7271
After Hours:
2.7271
2.7271
+
Procaps Group S.A stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.69 pivot point. If it approaches the $2.50 support level, significant changes may occur.
Previous Close:
$2.7271
Open:
$0
24h Volume:
0
Market Cap:
$307.68M
Revenue:
$414.10M
Net Income/Loss:
$52.20M
P/E Ratio:
0.00
EPS:
0.6525
Net Cash Flow:
$34.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Procaps Group S.A Stock (PROC) Company Profile
Name
Procaps Group S.A
Sector
Phone
356 7995 6138
Address
9 rue de Bitbourg, Luxembourg City
Procaps Group S.A Stock (PROC) Latest News
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday
Benzinga
Coherus BioSciences, Ascent Industries And 3 Stocks To Watch Heading Into Wednesday
Benzinga
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
Zacks Investment Research
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Pacira (PCRX) Misses Q3 Earnings and Revenue Estimates
Zacks Investment Research
Procaps Group S.A Stock (PROC) Financials Data
Procaps Group S.A (PROC) Revenue 2024
PROC reported a revenue (TTM) of $414.10 million for the quarter ending September 30, 2023, a -4.80% decline year-over-year.
Procaps Group S.A (PROC) Net Income 2024
PROC net income (TTM) was $52.20 million for the quarter ending September 30, 2023, a -13.15% decrease year-over-year.
Procaps Group S.A (PROC) Cash Flow 2024
PROC recorded a free cash flow (TTM) of $34.06 million for the quarter ending September 30, 2023, a +252.50% increase year-over-year.
Procaps Group S.A (PROC) Earnings per Share 2024
PROC earnings per share (TTM) was $0.52 for the quarter ending September 30, 2023, a -6.84% decline year-over-year.
About Procaps Group S.A
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg.
Cap:
|
Volume (24h):